A team of scientists at GE Global Research, the technology development arm for GE has launched a study with Memorial Sloan-Kettering Cancer Center (MSKCC) to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.
One of the primary issues in cancer diagnosis today is the limited amount of molecular information pathologists have about a particular cancer. At the time of diagnosis, little is determined about the characteristics of cancer itself such as how fast or slow it may be growing. New breakthroughs in molecular medicine are promising to change this paradigm.
Last October, GE scientists announced a major cancer research breakthrough in molecular pathology that is unlocking information about cancer previously hidden from view. This molecular information will not only increase our understanding of cancer; it could improve treatment selection for patients. This is particularly true for patients with early stage colon cancer.
New molecular analysis from cancer mapping tools such as GE’s have the potential to change this paradigm, so that these cases can be identified and directed to the appropriate treatment.
As part of the study, GE and MSKCC will collaborate to evaluate biomarkers for their prognostic value to segregate high from low risk early stage colon cancers. Scientists and investigators from GE and MSKCC will work together to first identify cancer cases, acquire and process cancer tissues, and collect treatment outcome information, then biochemically and statistically analyze the molecular profiles for the cancer tissues, and relate the molecular profiles to treatment outcomes.